Genetic and non-genetic instability in tumor progression: Link between the fitness landscape and the epigenetic landscape of cancer cells

Cancer and Metastasis Reviews

Volumn 32, Issue 3-4, 2013, Pages 423-448

  Huang, Sui ^a  

^a INSTITUTE FOR SYSTEMS BIOLOGY   (United States)

Author keywords

Cancer attractor; Cancer stem cell; Epigenetic landscape; Gene instability non genetic heterogeneity; Plasticity

Indexed keywords

ANTINEOPLASTIC AGENT; PACLITAXEL; PROTEIN TYROSINE KINASE INHIBITOR; TRANSCRIPTOME;

ARTICLE; BREAST CANCER; CANCER CELL; CANCER CHEMOTHERAPY; CANCER STEM CELL; CELL DEATH; CELL MUTANT; CELL TYPE; CHROMOSOMAL INSTABILITY; CHROMOSOME ABERRATION; DNA DAMAGE; EPIGENETIC LANDSCAPE; EPIGENETICS; GENE EXPRESSION; GENE REGULATORY NETWORK; GENOME; GENOTYPE PHENOTYPE CORRELATION; HUMAN; HUMAN CELL; METASTASIS; MUTAGENESIS; NON GENETIC INSTABILITY; PRIORITY JOURNAL;

ANIMALS; DISEASE PROGRESSION; EPIGENESIS, GENETIC; GENOMIC INSTABILITY; HUMANS; NEOPLASMS; PHENOTYPE;

EID: 84890313470     PISSN: 01677659     EISSN: 15737233     Source Type: Journal    
DOI: 10.1007/s10555-013-9435-7     Document Type: Article

References (136)

1. Lengauer, C., Kinzler, K. W., & Vogelstein, B. (1998). Genetic instabilities in human cancers. Nature, 396(6712), 643-649.
2. Cahill, D. P., Kinzler, K. W., Vogelstein, B., & Lengauer, C. (1999). Genetic instability and Darwinian selection in tumours. Trends in Cell Biology, 9(12), M57-M60.
3. Attolini, C. S., & Michor, F. (2009). Evolutionary theory of cancer. Annals of the New York Academy of Sciences, 1168, 23-51. doi: 10.1111/j.1749-6632.2009.04880.x (Review).
4. Nowak, M. A., Michor, F., & Iwasa, Y. (2006). Genetic instability and clonal expansion. Journal of Theoretical Biology, 241(1), 26-32. doi: 10.1016/j.jtbi.2005.11.012.
5. Heng, H. H., Stevens, J. B., Bremer, S. W., Ye, K. J., Liu, G., & Ye, C. J. (2010). The evolutionary mechanism of cancer. Journal of Cellular Biochemistry, 109(6), 1072-1084. doi: 10.1002/jcb.22497.
6. McCullough, K. D., Coleman, W. B., Ricketts, S. L., Wilson, J. W., Smith, G. J., & Grisham, J. W. (1998). Plasticity of the neoplastic phenotype in vivo is regulated by epigenetic factors. Proceedings of the National Academy of Sciences of the United States of America, 95(26), 15333-15338.
7. Gupta, P. B., Fillmore, C. M., Jiang, G., Shapira, S. D., Tao, K., Kuperwasser, C., et al. (2011). Stochastic state transitions give rise to phenotypic equilibrium in populations of cancer cells. Cell, 146(4), 633-644. doi: 10.1016/j.cell.2011.07.026 (Research support, non-U.S. government).
8. Chaffer, C. L., Brueckmann, I., Scheel, C., Kaestli, A. J., Wiggins, P. A., Rodrigues, L. O., et al. (2011). Normal and neoplastic nonstem cells can spontaneously convert to a stem-like state. Proceedings of the National Academy of Sciences of the United States of America, 108(19), 7950-7955. doi: 10.1073/pnas.1102454108.
9. Roesch, A., Fukunaga-Kalabis, M., Schmidt, E. C., Zabierowski, S. E., Brafford, P. A., Vultur, A., et al. (2010). A temporarily distinct subpopulation of slow-cycling melanoma cells is required for continuous tumor growth. Cell, 141(4), 583-594. doi: 10.1016/j.cell.2010.04.020.
10. Dean, M., Fojo, T., & Bates, S. (2005). Tumour stem cells and drug resistance. Nature Reviews. Cancer, 5(4), 275-284.
11. Hoek, K. S., & Goding, C. R. (2010). Cancer stem cells versus phenotype-switching in melanoma. Pigment Cell & Melanoma Research, 23(6), 746-759. doi: 10.1111/j.1755-148X.2010.00757.x (Comparative study review).
12. Sharma, S. V., Lee, D. Y., Li, B., Quinlan, M. P., Takahashi, F., Maheswaran, S., et al. (2010). A chromatin-mediated reversible drug-tolerant state in cancer cell subpopulations. Cell, 141(1), 69-80. doi: 10.1016/j.cell.2010.02.027.
13. Huang, S. (2012). Tumor progression: chance and necessity in Darwinian and Lamarckian somatic (mutationless) evolution. Progress in Biophysics and Molecular Biology, 110(1), 69-86.
14. Holmberg, J., & Perlmann, T. (2012). Maintaining differentiated cellular identity. Nature Reviews. Genetics, 13(6), 429-439. doi: 10.1038/nrg3209 (Research support, non-U.S. government. Review).
15. Sawyers, C. L., Denny, C. T., & Witte, O. N. (1991). Leukemia and the disruption of normal hematopoiesis. Cell, 64(2), 337-350 (Research support, non-U.S. government. Review).
16. Virchow, R. L. K. (1978). Cellular pathology (1859th ed., pp. 204-207). London: John Churchill.
17. Deutscher, G. (2010). Through the language glass: why the world looks different in other languages (1st ed.). New York: Macmillan.
18. Huang, S. (2012). The molecular and mathematical basis of Waddington's epigenetic landscape: a framework for post-Darwinian biology. BioEssays, 34(2), 149-155.
19. Sieber, O., Heinimann, K., & Tomlinson, I. (2005). Genomic stability and tumorigenesis. Seminars in Cancer Biology, 15(1), 61-66. doi: 10.1016/j.semcancer.2004.09.005.
20. Negrini, S., Gorgoulis, V. G., & Halazonetis, T. D. (2010). Genomic instability - an evolving hallmark of cancer. Nature Reviews. Molecular Cell Biology, 11(3), 220-228. doi: 10.1038/nrm2858.
21. Beckman, R. A. (2010). Efficiency of carcinogenesis: is the mutator phenotype inevitable? Seminars in Cancer Biology, 20(5), 340-352. doi: 10.1016/j.semcancer.2010.10.004 (Review).
22. Bielas, J. H., & Loeb, L. A. (2005). Mutator phenotype in cancer: timing and perspectives. Environmental and Molecular Mutagenesis, 45(2-3), 206-213.
23. Huang, S., & Ingber, D. E. (2000). Shape-dependent control of cell growth, differentiation, and apoptosis: switching between attractors in cell regulatory networks. Experimental Cell Research, 261(1), 91-103.
24. Huang, S. (2009). Non-genetic heterogeneity of cells in development: more than just noise. Development, 136(23), 3853-3862. doi: 10.1242/dev.035139.
25. Altschuler, S. J., & Wu, L. F. (2010). Cellular heterogeneity: do differences make a difference? Cell, 141(4), 559-563. doi: 10.1016/j.cell.2010. 04.033.
26. Stewart, J. M., Shaw, P. A., Gedye, C., Bernardini, M. Q., Neel, B. G., & Ailles, L. E. (2011). Phenotypic heterogeneity and instability of human ovarian tumor-initiating cells. Proceedings of the National Academy of Sciences of the United States of America, 108(16), 6468-6473. doi: 10.1073/pnas. 1005529108.
27. Baum, B., Settleman, J., & Quinlan, M. P. (2008). Transitions between epithelial and mesenchymal states in development and disease. Semin Cell Dev Biol, 19(3), 294-308. doi: 10.1016/j.semcdb.2008.02.001.
28. Singh, A., & Settleman, J. (2010). EMT, cancer stem cells and drug resistance: an emerging axis of evil in the war on cancer. Oncogene, 29(34), 4741-4751. doi: 10.1038/onc.2010.215.
29. Bonifer, C. (2005). Epigenetic plasticity of hematopoietic cells. Cell Cycle, 4(2), 211-214.
30. Frisen, J. (2002). Stem cell plasticity? Neuron, 35(3), 415-418.
31. Joshi, C. V., & Enver, T. (2002). Plasticity revisited. Current Opinion in Cell Biology, 14(6), 749-755.
32. Raff, M. (2003). Adult stem cell plasticity: fact or artifact? Annual Review of Cell and Developmental Biology, 19, 1-22.
33. Gotzmann, J., Mikula, M., Eger, A., Schulte-Hermann, R., Foisner, R., Beug, H., et al. (2004). Molecular aspects of epithelial cell plasticity: implications for local tumor invasion and metastasis. Mutation Research, 566(1), 9-20.
34. Spencer, S. L., Gerety, R. A., Pienta, K. J., & Forrest, S. (2006). Modeling somatic evolution in tumorigenesis. PLoS Computational Biology, 2(8), e108.
35. Vogelstein, B., & Kinzler, K. W. (1993). The multistep nature of cancer. Trends in Genetics, 9(4), 138-141.
36. Hanahan, D., & Weinberg, R. A. (2011). Hallmarks of cancer: the next generation. Cell, 144(5), 646-674. doi: 10.1016/j.cell.2011.02.013 (Research support, N.I.H. Extramural review).
37. Huang, S. (2011). Systems biology of stem cells: three useful perspectives to help overcome the paradigm of linear pathways. Philosophical Transactions of the Royal Society of London. Series B, Biological Sciences, 366(1575), 2247-2259. doi: 10.1098/rstb.2011.0008.
38. Huang, S., & Kauffman, S. (2009). Complex gene regulatory networks - from structure to biological observables: cell fate determination. In R. A. Meyers (Ed.), Encyclopedia of complexity and systems science. Heidelberg: Springer, 1180-1213.
39. Huang, S. (2009). Reprogramming cell fates: reconciling rarity with robustness. BioEssays, 31(5), 546-560. doi: 10.1002/bies.200800189.
40. Eldar, A., & Elowitz, M. B. (2010). Functional roles for noise in genetic circuits. Nature, 467(7312), 167-173. doi: 10.1038/nature09326.
41. Kaern, M., Elston, T. C., Blake, W. J., & Collins, J. J. (2005). Stochasticity in gene expression: from theories to phenotypes. Nature Reviews. Genetics, 6(6), 451-464.
42. Raj, A., & van Oudenaarden, A. (2008). Nature, nurture, or chance: stochastic gene expression and its consequences. Cell, 135(2), 216-226. doi: 10.1016/j.cell.2008.09.050.
43. Huang, S. (2010). Cell lineage determination in state space: a systems view brings flexibility to dogmatic canonical rules. PLoS Biology, 8(5), e1000380. doi: 10.1371/journal.pbio.1000380.
44. Zhou, J. X., Aliyu, M. D., Aurell, E., & Huang, S. (2012). Quasi-potential landscape in complex multi-stable systems. Journal of the Royal Society, Interface, 9(77), 3539-3553. doi: 10.1098/rsif.2012.0434.
45. Ferrell, J. E., & Xiong, W. (2001). Bistability in cell signaling: how to make continuous processes discontinuous, and reversible processes irreversible. Chaos, 11(1), 227-236. doi: 10.1063/1.1349894.
46. Tyson, J. J., Chen, K. C., & Novak, B. (2003). Sniffers, buzzers, toggles and blinkers: dynamics of regulatory and signaling pathways in the cell. Current Opinion in Cell Biology, 15(2), 221-231.
47. Huang, S. (2001). Genomics, complexity and drug discovery: insights from Boolean network models of cellular regulation. Pharmacogenomics, 2(3), 203-222.
48. Waddington, C. H. (1957). The strategy of the genes. London: Allen and Unwin.
49. Kauffman, S. (1969). Homeostasis and differentiation in random genetic control networks. Nature, 224(215), 177-178.
50. Ptashne, M. (2007). On the use of the word 'epigenetic'. Current Biology, 17(7), R233-R236.
51. Bird, A. (2007). Perceptions of epigenetics. Nature, 447(7143), 396-398.
52. Holliday, R. (2005). DNA methylation and epigenotypes. Biochemistry (Mosc), 70(5), 500-504.
53. Kouzarides, T. (2007). Chromatin modifications and their function. Cell, 128(4), 693-705.
54. Kubicek, S., & Jenuwein, T. (2004). A crack in histone lysine methylation. Cell, 119(7), 903-906.
55. Trojer, P., & Reinberg, D. (2006). Histone lysine demethylases and their impact on epigenetics. Cell, 125(2), 213-217.
56. Bonifer, C., Hoogenkamp, M., Krysinska, H., & Tagoh, H. (2008). How transcription factors program chromatin - lessons from studies of the regulation of myeloid-specific genes. Seminars in Immunology, 20(4), 257-263. doi: 10.1016/j.smim.2008.05.001.
57. Suter, D. M., Molina, N., Naef, F., & Schibler, U. (2011). Origins and consequences of transcriptional discontinuity. Current Opinion in Cell Biology, 23(6), 657-662. doi: 10.1016/j.ceb.2011.09.004.
58. Lynch, M. (2007). Colloquium papers: the frailty of adaptive hypotheses for the origins of organismal complexity. Proceedings of the National Academy of Sciences of the United States of America, 104(Suppl 1), 8597-8604.
59. Nowak, M. A. (2006). Evolutionary dynamics: exploring the equations of life (1st ed.). Cambridge, MA: Belknap.
60. Wright, S. (1945). The differential equation of the distribution of gene frequencies. Proceedings of the National Academy of Sciences of the United States of America, 31(12), 382-389.
61. Kauffman, S. A. (1993). The origins of order. New York: Oxford University Press.
62. Galhardo, R. S., Hastings, P. J., & Rosenberg, S. M. (2007). Mutation as a stress response and the regulation of evolvability. Critical Reviews in Biochemistry and Molecular Biology, 42(5), 399-435. doi: 10.1080/ 10409230701648502 (Research support, N.I.H. Extramural review).
63. Brutovsky, B., & Horvath, D. (2010). Optimization aspects of carcinogenesis. Medical Hypotheses, 74(5), 922-927. doi: 10.1016/j.mehy.2009.10. 019 (Research support, non-U.S. government).
64. Bielas, J. H., Loeb, K. R., Rubin, B. P., True, L. D., & Loeb, L. A. (2006). Human cancers express a mutator phenotype. Proceedings of the National Academy of Sciences of the United States of America, 103(48), 18238-18242.
65. Cairns, J. (1975). Mutation selection and the natural history of cancer. Nature, 255(5505), 197-200.
66. Klein, C. A. (2009). Parallel progression of primary tumours and metastases. Nature Reviews. Cancer, 9(4), 302-312. doi: 10.1038/nrc2627.
67. Bernards, R., & Weinberg, R. A. (2002). A progression puzzle. Nature, 418(6900), 823.
68. Brock, A., Chang, H., & Huang, S. (2009). Non-genetic heterogeneity - a mutation-independent driving force for the somatic evolution of tumours. Nature Reviews. Genetics, 10(5), 336-342. doi: 10.1038/nrg2556.
69. Gould, S. J. (1997). Darwinian fundamentalism. New York Review of Books (June 12), pp. 34-37.
70. Gould, S. J., & Lewontin, R. C. (1979). The spandrels of San Marco and the Panglossian paradigm: a critique of the adaptationist programme. Proceedings of the Royal Society of London. Series B: Biological Sciences, 205(1161), 581-598.
71. Lewontin, R. C. (2000). The triple helix: gene, organism, and environment (2001st ed.). Cambridge, MA: Harvard University Press.
72. Rose, S., Kamin, L. J., & Lewontin, R. C. (1985). Not in our genes: biology, ideology, and human nature. New York: Pantheon.
73. Pigliucci, M. (2009). An extended synthesis for evolutionary biology. Annals of the New York Academy of Sciences, 1168, 218-228. doi: 10.1111/j.1749-6632.2009.04578.x.
74. Noble, D. (2011). Neo-Darwinism, the modern synthesis and selfish genes: are they of use in physiology? The Journal of Physiology, 589(Pt 5), 1007-1015. doi: 10.1113/jphysiol.2010.201384 (Research support, non-U.S. government. Review).
75. Eldredge, N., & Gould, S. J. (1997). On punctuated equilibria. Science, 276(5311), 338-341 (Comment letter).
76. Caporale, L. H. (2009). Putting together the pieces: evolutionary mechanisms at work within genomes: can we suggest molecular underpinnings of punctuated equilibria and the Cambrian explosion? BioEssays, 31(7), 700-702. doi: 10.1002/bies.200900067.
77. Gould, S. J. (1994). Tempo and mode in the macroevolutionary reconstruction of Darwinism. Proceedings of the National Academy of Sciences of the United States of America, 91(15), 6764-6771 (Review).
78. Heng, H. H., Bremer, S. W., Stevens, J., Ye, K. J., Miller, F., Liu, G., et al. (2006). Cancer progression by non-clonal chromosome aberrations. Journal of Cellular Biochemistry, 98(6), 1424-1435. doi: 10.1002/jcb.20964 (Comparative study. Research support, non-U.S. government. Review).
79. Heng, H. H., Stevens, J. B., Bremer, S. W., Liu, G., Abdallah, B. Y., & Ye, C. J. (2011). Evolutionary mechanisms and diversity in cancer. Advances in Cancer Research, 112, 217-253. doi: 10.1016/B978-0-12-387688-1. 00008-9 (Research support, non-U.S. government, non-P.H.S. Review).
80. Stephens, P. J., Greenman, C. D., Fu, B., Yang, F., Bignell, G. R., Mudie, L. J., et al. (2011). Massive genomic rearrangement acquired in a single catastrophic event during cancer development. Cell, 144(1), 27-40. doi: 10.1016/j.cell.2010.11.055.
81. Huang, S., Ernberg, I., & Kauffman, S. (2009). Cancer attractors: a systems view of tumors from a gene network dynamics and developmental perspective. Seminars in Cell & Developmental Biology, 20(7), 869-876. doi: 10.1016/j.semcdb.2009.07.003.
82. Davies, P. C., & Lineweaver, C. H. (2011). Cancer tumors as Metazoa 1.0: tapping genes of ancient ancestors. Physical Biology, 8((1), 015001. doi: 10.1088/1478-3975/8/1/015001 (Research support, N.I.H., Extramural).
83. Ben-Jacob, E., Coffey, D. S., & Levine, H. (2012). Bacterial survival strategies suggest rethinking cancer cooperativity. Trends in Microbiology, 20(9), 403-410. doi: 10.1016/j.tim.2012.06.001.
84. Kauffman, S. (1971). Differentiation of malignant to benign cells. Journal of Theoretical Biology, 31(3), 429-451.
85. Huang, S. (2011). On the intrinsic inevitability of cancer: from foetal to fatal attraction. Seminars in Cancer Biology, 21(3), 183-199. doi: 10.1016/j.semcancer.2011.05.003.
86. Aldana, M., Balleza, E., Kauffman, S., & Resendiz, O. (2007). Robustness and evolvability in genetic regulatory networks. Journal of Theoretical Biology, 245(3), 433-448.
87. Torres-Sosa, C., Huang, S., & Aldana, M. (2012). Criticality is an emergent property of genetic networks that exhibit evolvability. PLoS Computational Biology, 8(9), e1002669. doi: 10.1371/journal.pcbi.1002669 (Research support, non-U.S. government).
88. Sonnenschein, C., & Soto, A. M. (1998). The society of cells: cancer and control of cell proliferation. Philadelphia, PA: Garland Science.
89. Raff, M. C. (1992). Social controls on cell survival and cell death. Nature, 356(6368), 397-400.
90. Paulovich, A. G., Toczyski, D. P., & Hartwell, L. H. (1997). When checkpoints fail. Cell, 88(3), 315-321.
91. Hernando, E., Nahle, Z., Juan, G., Diaz-Rodriguez, E., Alaminos, M., Hemann, M., et al. (2004). Rb inactivation promotes genomic instability by uncoupling cell cycle progression from mitotic control. Nature, 430(7001), 797-802.
92. Mantel, C., Guo, Y., Lee, M. R., Kim, M. K., Han, M. K., Shibayama, H., et al. (2007). Checkpoint-apoptosis uncoupling in human and mouse embryonic stem cells: a source of karyotpic instability. Blood, 109(10), 4518-4527. doi: 10.1182/blood-2006-10-054247 (Research support, N.I.H., non-U.S. government. Extramural).
93. Erenpreisa, J., & Cragg, M. S. (2007). Cancer: a matter of life cycle? Cell Biology International, 31(12), 1507-1510. doi: 10.1016/j.cellbi. 2007.08.013 (Review).
94. Balleza, E., Alvarez-Buylla, E. R., Chaos, A., Kauffman, A., Shmulevich, I., & Aldana, M. (2008). Critical dynamics in genetic regulatory networks: examples from four kingdoms. PLoS One, 3, e2456.
95. Shmulevich, I., Kauffman, S. A., & Aldana, M. (2005). Eukaryotic cells are dynamically ordered or critical but not chaotic. Proceedings of the National Academy of Sciences of the United States of America, 102(38), 13439-13444.
96. Mitsiadis, T. A., Caton, J., & Cobourne, M. (2006). Waking-up the sleeping beauty: recovery of the ancestral bird odontogenic program. Journal of Experimental Zoology. Part B, Molecular and Developmental Evolution, 306(3), 227-233. doi: 10.1002/jez.b.21094 (Research support, non-U.S. government. Comparative study).
97. Newman, S. A. (2011). Thermogenesis, muscle hyperplasia, and the origin of birds. BioEssays, 33(9), 653-656. doi: 10.1002/bies.201100061 (Research support, U.S. government, non-P.H.S.).
98. Kitada, K., Taima, A., Ogasawara, K., Metsugi, S., & Aikawa, S. (2011). Chromosome-specific segmentation revealed by structural analysis of individually isolated chromosomes. Genes, Chromosomes & Cancer, 50(4), 217-227. doi: 10.1002/gcc.20847.
99. Li, R., Yerganian, G., Duesberg, P., Kraemer, A., Willer, A., Rausch, C., et al. (1997). Aneuploidy correlated 100 % with chemical transformation of Chinese hamster cells. Proceedings of the National Academy of Sciences of the United States of America, 94(26), 14506-14511.
100. Clark, W. H. (1991). Tumour progression and the nature of cancer. British Journal of Cancer, 64(4), 631-644.
101. Mitchison, T. J. (2012). The proliferation rate paradox in antimitotic chemotherapy. Molecular Biology of the Cell, 23(1), 1-6. doi: 10.1091/mbc.E10-04-0335 (Research support, N.I.H. Extramural).
102. Persons, D. L., Yazlovitskaya, E. M., Cui, W., & Pelling, J. C. (1999). Cisplatin-induced activation of mitogen-activated protein kinases in ovarian carcinoma cells: inhibition of extracellular signal-regulated kinase activity increases sensitivity to cisplatin. Clinical Cancer Research, 5(5), 1007-1014 (Research support, U.S. government, P.H.S. Comparative study).
103. Sims, A. H., Zweemer, A. J., Nagumo, Y., Faratian, D., Muir, M., Dodds, M., et al. (2012). Defining the molecular response to trastuzumab, pertuzumab and combination therapy in ovarian cancer. British Journal of Cancer, 106(11), 1779-1789. doi: 10.1038/bjc.2012.176 (Research support, non-U.S. government).
104. Levsky, J. M., & Singer, R. H. (2003). Gene expression and the myth of the average cell. Trends in Cell Biology, 13(1), 4-6.
105. Chang, H. H., Hemberg, M., Barahona, M., Ingber, D. E., & Huang, S. (2008). Transcriptome-wide noise controls lineage choice in mammalian progenitor cells. Nature, 453(7194), 544-547.
106. Cohen, A. A., Geva-Zatorsky, N., Eden, E., Frenkel-Morgenstern, M., Issaeva, I., Sigal, A., et al. (2008). Dynamic proteomics of individual cancer cells in response to a drug. Science, 322, 1511-1516.
107. Spencer, S. L., Gaudet, S., Albeck, J. G., Burke, J. M., & Sorger, P. K. (2009). Non-genetic origins of cell-to-cell variability in TRAIL-induced apoptosis. Nature, 459(7245), 428-432. doi: 10.1038/nature08012.
108. Darwin, C. (1869). On the origin of species by means of natural selection, or the preservation of favoured races in the struggle for life (5th ed., pp. 91-92). London: John Murray.
109. Nietzsche, F. (1998). Twilight of the idols (D. Large, trans.). Oxford: Oxford University Press.
110. Dirks, P. (2010). Cancer stem cells: invitation to a second round. Nature, 466(7302), 40-41. doi: 10.1038/466040a.
111. Gupta, P. B., Chaffer, C. L., & Weinberg, R. A. (2009). Cancer stem cells: mirage or reality? Nature Medicine, 15(9), 1010-1012. doi: 10.1038/nm0909-1010.
112. Hill, R. P., & Perris, R. (2007). "Destemming" cancer stem cells. Journal of the National Cancer Institute, 99(19), 1435-1440.
113. Jordan, C. T. (2009). Cancer stem cells: controversial or just misunderstood? Cell Stem Cell, 4(3), 203-205. doi: 10.1016/j.stem.2009.02.003.
114. Kelly, P. N., Dakic, A., Adams, J. M., Nutt, S. L., & Strasser, A. (2007). Tumor growth need not be driven by rare cancer stem cells. Science, 317(5836), 337. doi: 10.1126/science.1142596.
115. Lobo, N. A., Shimono, Y., Qian, D., & Clarke, M. F. (2007). The biology of cancer stem cells. Annual Review of Cell and Developmental Biology, 23, 675-699. doi: 10.1146/annurev.cellbio.22.010305.104154.
116. Reya, T., Morrison, S. J., Clarke, M. F., & Weissman, I. L. (2001). Stem cells, cancer, and cancer stem cells. Nature, 414(6859), 105-111.
117. Blick, T., Widodo, E., Hugo, H., Waltham, M., Lenburg, M. E., Neve, R. M., et al. (2008). Epithelial mesenchymal transition traits in human breast cancer cell lines. Clinical & Experimental Metastasis, 25(6), 629-642.
118. Deka, J., Wiedemann, N., Anderle, P., Murphy-Seiler, F., Bultinck, J., Eyckerman, S., et al. (2010). Bcl9/Bcl9l are critical for Wnt-mediated regulation of stem cell traits in colon epithelium and adenocarcinomas. Cancer Research, 70(16), 6619-6628. doi: 10.1158/0008-5472.CAN-10-0148.
119. Mani, S. A., Guo, W., Liao, M. J., Eaton, E. N., Ayyanan, A., Zhou, A. Y., et al. (2008). The epithelial-mesenchymal transition generates cells with properties of stem cells. Cell, 133(4), 704-715.
120. Donnenberg, V. S., & Donnenberg, A. D. (2005). Multiple drug resistance in cancer revisited: the cancer stem cell hypothesis. The Journal of Clinical Pharmacology, 45(8), 872-877.
121. Elliot, A., Adams, J., & Al-Hajj, M. (2010). The ABCs of cancer stem cell drug resistance. IDrugs, 13(9), 632-635.
122. Lee, G. Y., Shim, J. S., Cho, B., Jung, J. Y., Lee, D. S., & Oh, I. H. (2011). Stochastic acquisition of a stem cell-like state and drug tolerance in leukemia cells stressed by radiation. International Journal of Hematology, 93(1), 27-35. doi: 10.1007/s12185-010-0734-2 (Research support, non-U.S. government).
123. Ghisolfi, L., Keates, A. C., Hu, X., Lee, D. K., & Li, C. J. (2012). Ionizing radiation induces stemness in cancer cells. PLoS One, 7(8), e43628. doi: 10.1371/journal.pone.0043628 (Research support, non-U.S. government).
124. Andarawewa, K. L., Erickson, A. C., Chou, W. S., Costes, S. V., Gascard, P., Mott, J. D., et al. (2007). Ionizing radiation predisposes nonmalignant human mammary epithelial cells to undergo transforming growth factor beta induced epithelial to mesenchymal transition. Cancer Research, 67(18), 8662-8670. doi: 10.1158/0008-5472.CAN-07-1294 (Research support, U.S. government, non-P.H.S.).
125. Arumugam, T., Ramachandran, V., Fournier, K. F., Wang, H., Marquis, L., Abbruzzese, J. L., et al. (2009). Epithelial to mesenchymal transition contributes to drug resistance in pancreatic cancer. Cancer Research, 69(14), 5820-5828. doi: 10.1158/0008-5472.CAN-08-2819.
126. Li, Q. Q., Xu, J. D., Wang, W. J., Cao, X. X., Chen, Q., Tang, F., et al. (2009). Twist1-mediated adriamycin-induced epithelial-mesenchymal transition relates to multidrug resistance and invasive potential in breast cancer cells. Clinical Cancer Research, 15(8), 2657-2665. doi: 10.1158/1078-0432.CCR-08-2372 (Research support, non-U.S. government).
127. Li, Q. Q., Chen, Z. Q., Cao, X. X., Xu, J. D., Xu, J. W., Chen, Y. Y., et al. (2011). Involvement of NF-kappaB/miR-448 regulatory feedback loop in chemotherapy-induced epithelial-mesenchymal transition of breast cancer cells. Cell Death and Differentiation, 18(1), 16-25. doi: 10.1038/cdd.2010.103 (Research support, non-U.S. government).
128. Wang, Z., Li, Y., Kong, D., Banerjee, S., Ahmad, A., Azmi, A. S., et al. (2009). Acquisition of epithelial-mesenchymal transition phenotype of gemcitabine-resistant pancreatic cancer cells is linked with activation of the notch signaling pathway. Cancer Research, 69(6), 2400-2407. doi: 10.1158/0008-5472.CAN-08-4312 (Research support, N.I.H., non-U.S. government. Extramural).
129. Chaudhary, P. M., & Roninson, I. B. (1993). Induction of multidrug resistance in human cells by transient exposure to different chemotherapeutic drugs. Journal of the National Cancer Institute, 85(8), 632-639.
130. Abolhoda, A., Wilson, A. E., Ross, H., Danenberg, P. V., Burt, M., & Scotto, K. W. (1999). Rapid activation of MDR1 gene expression in human metastatic sarcoma after in vivo exposure to doxorubicin. Clinical Cancer Research, 5(11), 3352-3356.
131. Stein, U., Jurchott, K., Walther, W., Bergmann, S., Schlag, P. M., & Royer, H. D. (2001). Hyperthermia-induced nuclear translocation of transcription factor YB-1 leads to enhanced expression of multidrug resistance-related ABC transporters. The Journal of Biological Chemistry, 276(30), 28562-28569. doi: 10.1074/jbc.M100311200 (Research support, non-U.S. government).
132. Chin, K. V., Tanaka, S., Darlington, G., Pastan, I., & Gottesman, M. M. (1990). Heat shock and arsenite increase expression of the multidrug resistance (MDR1) gene in human renal carcinoma cells. The Journal of Biological Chemistry, 265(1), 221-226.
133. Pleasance, E. D., Cheetham, R. K., Stephens, P. J., McBride, D. J., Humphray, S. J., Greenman, C. D., et al. (2010). A comprehensive catalogue of somatic mutations from a human cancer genome. Nature, 463(7278), 191-196. doi: 10.1038/nature08658.
134. Yates, L. R., & Campbell, P. J. (2012). Evolution of the cancer genome. Nature Reviews. Genetics, 13(11), 795-806. doi: 10.1038/nrg3317.
135. Kreso, A., O'Brien, C. A., van Galen, P., Gan, O. I., Notta, F., Brown, A. M., et al. (2013). Variable clonal repopulation dynamics influence chemotherapy response in colorectal cancer. Science, 339(6119), 543-548. doi: 10.1126/science.1227670.
136. Nobili, S., Landini, I., Mazzei, T., & Mini, E. (2012). Overcoming tumor multidrug resistance using drugs able to evade P-glycoprotein or to exploit its expression. Medicinal Research Reviews, 32, 1220-1262. doi: 10.1002/med.20239.